Illustrative image – not actual.Piramal Healthcare has signed a pact with Japan's Fujifilm Diosynth for a contract manufacturing deal. The proposed plan dealt with developing antibody drug conjugates (ADC), an area in bio-pharma which focuses on targeted therapy, specifically in the treatment of cancer.
In targeted therapy, specific cancer-causing cells are targeted instead of the traditional chemotherapy which kills good cells in the process. The partnership will cover more than 150 bio-pharmaceuticals and over 300 batches of ADC which would cover over 30 different new chemical entities.
Source: Economic Times
